




Supplemental data




**Figure S1: ZIKV-PF13 does not cause significant activation of apoptosis until late in infection in U251MG cells.** U251MG was infected with ZIKV PF13 strain isolate at MOI of 1 and for 96h. (A) Percentage of U251MG infected cells immunostained with anti-BAX antibody at 24, 48 and 96 hours post infection. (B) The infectious virus was collected in supernatant of infected cells at 24, 48, 72 and 96hours post infection for PFU assay.



**Figure S2: ZIKV-PF13 provides a protection against cell death induced.** A549 was infected with ZIKV-PF13 isolate at MOI of 1 for 8 hours and treated with etoposide 2 h post infection (2hpi). The percentage of A549 cells immunostained with anti-BAX antibody was followed (A). Vero cells was infected with ZIKV-PF13 isolate at MOI of 1 for 8 h and treated with blasticidin followed by MTT assay (B) or Caspase 3/7 activity (C). Values represent the mean and standard deviation of three independent experiments (\*p<0,05).



**Figure S3: ZIKV-MR766 does not cause significant activation of apoptosis until late in infection and ZIKV-MR766 is able to control cell death.** A549 was infected with MR766<sup>MC</sup> clone at MOI of 1 and for 96h. The percentage of A549 infected cells immunostained with anti-BAX antibody at 24, 48 and 72 h post infection (A). The infectious virus was collected in supernatant of infected cells at 24, 48, 72 and 96 h post infection for PFU assay (B). A549 was infected with MR766 molecular clone at MOI of 1 for 8 hours and treated with TNF $\alpha$  and cycloheximide (CHX) 2 h before infection (2hbi) or 2 h post infection (2hpi). Percentage of A549 cells immunostained with anti-BAX antibody (C). Values represent the mean and standard deviation of three independent experiments (\*p<0,05).



**Figure S4: Cell death protection is acquired through ZIKV-MR766 replication in A549 cells.**  
A549 cells were transfected with fragment of ISA methods to generated replicon for ZIKV-MR766 or with pEGFP-N1 (A). 48h after transfection A549 cells were treated with Etoposide for 16 h. Percentage of A549 cells immunostained with BAX antibody were followed. Values represent the mean and standard deviation of three independent experiments (\*p<0,05).